Stop endangering our children and our patients.
John Paulson and Mylan Pharmaceuticals
In the United States, 3.6 million people have an EpiPen prescription to treat severe allergic reactions.
Since John Paulson invested $1 billion in Mylan Pharmaceuticals, making him one of its biggest investors, the price of this crucial drug has spiked—by 32 percent over the past year and by a whopping 450 percent since 2007. As hedge funds and Mylan make profits, most families and schools simply can’t afford to pay $600 apiece for an EpiPen.
Sponsored by
To:
John Paulson and Mylan Pharmaceuticals
From:
[Your Name]
The price gouging of EpiPens is a matter of life and death for millions of people and most families simply can’t afford to pay $600 for EpiPens.
We demand that Mylan Pharmaceuticals ensures that lifesaving treatment is within reach for families.